Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function

Endocrine Journal

Volumn 59, Issue 4, 2012, Pages 297-304

  Sasaki, Junko ^a   Miwa, Takashi ^a   Odawara, Masato ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Eicosapentaenoic acid; Low density lipoprotein cholesterol; Residual risk; Vascular function

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID ETHYL ESTER; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EVENING DOSAGE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLETHYSMOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STRAIN GAUGE PLETHYSMOGRAPH; TREATMENT DURATION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPEREMIA; MALE; VASODILATION;

EID: 84860614282     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0394     Document Type: Article

References (28)

1. Lavie CJ, Milani RV, Mehra MR, Ventura HO (2009) Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 54(7):585-594
2. Sekikawa A, Curb JD, Ueshima H, El Saed A, Kadowaki T, Abbott RD, Evans RW, Rodriguez BL, Okamura T, Sutton Tyrrell K, Nakamura Y, Masaki K, Edmundowicz D, Kashiwagi A, Willcox BJ, Takamiya T, Mitsunami K, Seto TB, Murata K, White RL, Kuller LH (2008) Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a crosssectional study. J Am Coll Cardiol 52(6):417-424.
3. Tavani A, Pelucchi C, Negri E, Bertuzzi M, La Vecchia C (2001) N-3 Polyunsaturated fatty acids, fish, and nonfatal acute myocardial infarction. Circulation 104(19):2269-2272.
4. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567):1090-1098.
5. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K (2009) Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 206(2):535-539.
6. Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20(4):614-620.
7. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 53(6):450-467.
8. Higashi Y, Sasaki S (2001) A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol 87:121-125.
9. Ishibashi Y, Takahashi N, Shimada T, Sugamori T, Sakane T, Umeno T, Hirano Y, Oyake N, Murakami Y (2006) Short duration of reactive hyperemia in the forearm of subjects with multiple cardiovascular risk factors. Circ J 70(1):115-123.
10. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88(2):E14-22.
11. Bitar MS, Wahid S, Mustafa S, Al Saleh E, Dhaunsi GS, Al Mulla F (2005) Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol 511(1):53-64.
12. Libby P, Aikawa M (2002) Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8(11):1257-1262.
13. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL (2003) Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108(4):426-431.
14. Inoue T, Hayashi M, Takayanagi K, Morooka S (2002) Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 160:369-376.
15. Okuda Y, Kawashima K, Sawada T, Tsurumaru K, Asano M, Suzuki S, Soma M, Nakajima T, Yamashita K (1997) Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun 232(2):487-491.
16. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa Matsumoto M, Hirooka Y, Takeshita A (1999) Longterm treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 33(4):633-640.
17. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR (1993) Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:33-38.
18. Matsumoto T, Nakayama N, Ishida K, Kobayashi T, Kamata K (2009) Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. J Pharmacol Exp Ther 329(1):324-334.
19. Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD (1997) Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 96(10):3287-3293.
20. Shimano H, Arai H, Harada Shiba M, Ueshima H, Ohta T, Yamashita S, Gotoda T, Kiyohara Y, Hayashi T, Kobayashi J, Shimamoto K, Bujo H, Ishibashi S, Shirai K, Oikawa S, Saito Y, Yamada N (2008) Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 15:116-121.
21. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL (2001) Nonhigh-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161(11):1413-1419.
22. Robinson JG, Wang S, Smith BJ, Jacobson TA (2009) Meta-analysis of the relationship between non-highdensity lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53(4):316-322.
23. Vakkilainen J, Makimattila S, Seppala Lindroos A, Vehkavaara S, Lahdenpera S, Groop PH, Taskinen MR, Yki Jarvinen H (2000) Endothelial dysfunction in men with small LDL particles. Circulation 102(7):716-721.
24. Makimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenpera S, Syvanne M, Mantysaari M, Summanen P, Bergholm R, Taskinen MR, Yki Jarvinen H (1999) Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 22(6):973-981.
25. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101(15):1780-1784.
26. Hsueh WA, Lyon CJ, Quinones MJ (2004) Insulin resistance and the endothelium. Am J Med 117(2):109-117.
27. Wang D, Hirase T, Nitto T, Soma M, Node K (2009) Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells. J Cardiol 54(3):368-374.
28. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142(5):687-698.